{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"LENZ Therapeutics, Inc."},"Symbol":{"label":"Symbol","value":"LENZ"},"Address":{"label":"Address","value":"201 HASKINS WAY,SUITE 210, SOUTH SAN FRANCISCO, California, 94080, United States"},"Phone":{"label":"Phone","value":"+1 650 484-0886"},"Industry":{"label":"Industry","value":"Biotechnology: Biological Products (No Diagnostic Substances)"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Graphite Bio Inc is a clinical-stage gene-editing company harnessing gene integration to develop a new class of therapies to cure serious and life-threatening diseases. Its gene-editing platform allows to precisely correct mutations, replace entire disease-causing genes with normal genes, or insert new genes into predetermined, safe locations. Its lead product candidate GPH101 is a differentiated approach with the potential to directly correct the mutation that causes sickle cell disease (SCD) and restore normal adult hemoglobin (HgbA) expression. All of the company's long-lived assets are based in the United States."},"CompanyUrl":{"label":"Company Url","value":"https://www.graphitebio.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Evert B. Schimmelpennink","title":"President, CEO, Secretary & Director"},{"name":"Marc Odrich","title":"Chief Medical Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}